Daiwa Securities Group Inc. Acquires 8,435 Shares of Abbott Laboratories $ABT

Daiwa Securities Group Inc. boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 295,075 shares of the healthcare product maker’s stock after buying an additional 8,435 shares during the period. Daiwa Securities Group Inc.’s holdings in Abbott Laboratories were worth $36,970,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ABT. American National Bank of Texas lifted its stake in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after purchasing an additional 79 shares during the last quarter. Nia Impact Advisors LLC lifted its stake in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares during the last quarter. Connable Office Inc. lifted its stake in Abbott Laboratories by 0.5% during the third quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock worth $2,015,000 after purchasing an additional 81 shares during the last quarter. Park Place Capital Corp lifted its stake in Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after purchasing an additional 81 shares during the last quarter. Finally, Lantern Wealth Advisors LLC lifted its stake in Abbott Laboratories by 1.7% during the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Up 4.3%

Shares of NYSE:ABT opened at $90.71 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The company has a market cap of $157.99 billion, a PE ratio of 25.41, a P/E/G ratio of 1.45 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock’s 50-day moving average is $93.07 and its 200 day moving average is $109.44.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on ABT shares. Leerink Partners dropped their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. TD Cowen lowered their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, April 24th. Citigroup lowered their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Stifel Nicolaus lowered their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.